INFORMATION ONLY Changes to Requesting HLA/HPA Selected Apheresis Platelets Customer Letter #

Size: px

Start display at page:

Download "INFORMATION ONLY Changes to Requesting HLA/HPA Selected Apheresis Platelets Customer Letter #"

Norma Chambers
5 years ago
Views:

1 INFORMATION ONLY Changes to Requesting HLA/HPA Selected Apheresis Platelets Customer Letter # Head Office / Siège social Dear Customer, We are writing to inform you of changes to the Request for HLA/HPA Selected Apheresis Platelets form and the information recorded on the Cytapheresis tag attached to the HLA/HPA Apheresis Platelet product selected. The changes will be implemented on Revisions were made to standardize the process for requesting and tagging HLA/HPA selected Apheresis Platelets. The Canadian Blood Services department that your facility submits the Request for HLA/HPA Selected Apheresis Platelets, to will remain the same. The Request for HLA/HPA Selected Apheresis Platelets form has been divided into Sections. Important Information: Section I Patient Information: To be completed by requesting facility Section II Order Information: To be completed by requesting facility o Lab Reports are required. Transcribed results will not be accepted. o If the Prioritize TRALI Risk is indicated as YES the report generated to identify matching donors will exclude ALL female donors not just those with a history of pregnancy. o A Proposed transfusion schedule and estimated quantity should be provided in Section II if known. Section III is for Canadian Blood Services use only. Cytapheresis Tag HLA/HPA selected will be recorded beside Product type Name of Patient HLA/HPA Apheresis Platelet Selected for Name of requesting Hospital A Canadian Blood Services Site may also be recorded in some instances to ensure product is issued to the correct facility If the Donor of the HLA/HPA Apheresis Platelet was a female with history of pregnancy the statement For Intended Recipient Use Only. Female Donor with History of Pregnancy will appear on the tag. Examples of the Request for HLA/HPA Apheresis Platelets form and Cytapheresis Tag are attached and will be available in the hospital form section on

2 This Customer Letter can also be viewed at in the Hospitals section. If you have questions about this Customer Letter, please contact your local Hospital Liaison Specialist. Sincerely, Ian Mumford Chief Supply Chain Officer Encl.

3 Attachment I: Example of Cytapheresis Tag For Intended Recipient Use Only. Female Donor with History of Pregnancy. HLA/HPA Selected Site Name

Attachment II: Example of Request for HLA/HPA Selected Apheresis Platelets Section I: Patient Information Requesting Facility and CBS site: Telephone: (no abbreviations) Physician: Contact Name: Date

bleeding, sepsis, sequestration, anti-fungal drugs) Poor platelet increment (< 10,000), or CC (<7,500) on two occasions post platelet transfusion Presence of HLA/HPA alloantibodies from previous

4 Attachment II: Example of Request for HLA/HPA Selected Apheresis Platelets Section I: Patient Information Requesting Facility and CBS site: Telephone: (no abbreviations) Physician: Contact Name: Date Patient Name: Patient Identification Number: (Must match reports) Date of Birth Assess patient for the following: Thrombocytopenia with no evidence of peripheral platelet destruction (due to bleeding, sepsis, sequestration, anti-fungal drugs) Poor platelet increment (< 10,000), or CC (<7,500) on two occasions post platelet transfusion Presence of HLA/HPA alloantibodies from previous testing ABO/Rh: Diagnosis: Stem Cell or Bone Marrow Transplant N/A or Allo Auto Transplant Date Section II: Order information Note: Lab Reports are HLA Match HPA Match required. Transcribed HLA/HPA typing report: Attached Winnipeg PI tested results will not be accepted. HLA/HPA Antibody Report: Attached Winnipeg PI tested Pending Prioritize TRALI Risk Yes (Excludes female donors) No Anti-CMV Negative: Yes No (consult med if Anti-CMV Negative donor un-available) Treatment Start Date Estimated End Date Enter proposed transfusion schedule and estimated quantity if known Notify Canadian Blood Services immediately if order is no longer required or requirements change Example: 1 APLT 2xs a week Mondays and Thursdays For 2weeks Starting Monday Total doses: 4 Comments: SECTION III: Canadian Blood Services Use ONLY Forward PDS List or Component to CBS Site: Contact Name: Phone: Contact Fax: Comments:

5 SECTION III: Canadian Blood Services Use ONLY continued Patient Name: Donation Number TRALI Risk Assessment/ Tag Application Verified By: Assessment/ Applied By: No TRALI RISK Confirmation/ Un-Tagging Confirmation/ Verified by: Un-tagged By: Head Office / Siège social Comments

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD

$An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD$ Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different